PRODUCT INFORMATION

CL097

Item No. 39513

CAS Registry No.:	1026249-18-2
Formal Name:	2-(ethoxymethyl)-3H-imidazo[4,5-c] quinolin-4-amine
MF:	$C_{13}H_{14}N_4O$
FW:	242.3
Purity:	≥98%
UV/Vis.:	λ_{max}: 248, 322 nm
Supplied as:	A solid
Storage:	-20°C
Stability:	≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

CL097 is supplied as a solid. A stock solution may be made by dissolving the CL097 in the solvent of choice, which should be purged with an inert gas. CL097 is soluble in DMSO.

Description

CL097 is a dual agonist of toll-like receptor 7 (TLR7) and TLR8.[1] It induces activation of NF-κB in HEK293 cells expressing human TLR7 or TLR8 when used at concentrations of 0.1 and 1 µg/ml, respectively. CL097 induces TNF-α production and enhances LPS- or hyaluronic acid-induced TNF-α, IL-10, and IL-12 production in isolated human monocyte-derived macrophages.[2] *In vivo*, CL097 (5 mg/kg) increases pancreatic lymph node IFN-α levels in pre-diabetic non-obese diabetic (NOD) mice.[3]

References

1. Schön, M.P. and Schön, M. TLR7 and TLR8 as targets in cancer therapy. *Oncogene* **27(2)**, 190-199 (2008).
2. Petricevic, B., Wessner, B., Sachet, M., *et al*. CL097, a TLR7/8 ligand, inhibits TLR-4–dependent activation of IRAK-M and BCL-3 expression. *Shock* **32(5)**, 484-490 (2009).
3. Lee, A.S., Ghoreishi, M., Cheng, W.K., *et al*. Toll-like receptor 7 stimulation promotes autoimmune diabetes in the NOD mouse. *Diabetologia* **54(6)**, 1407-1416 (2011).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM